GTAC (Gene Therapy Advisory Committee) reports state of UK gene therapy R&D (research and development):
This article was originally published in Clinica
Executive Summary
The year 2000 saw a three-fold increase in the number of UK-based gene therapy trials, of which some are beginning to show "exciting results", says the UK's Gene Therapy Advisory Committee (GTAC) in its annual report for 2000. Over 400 patients have taken part in the 72 gene therapy trials conducted since 1992. Early results suggest a high degree of success in some of these studies, including severe combined immunodeficiency (SCID), melanoma, brain tumours, prostate cancer and lymphoma. The report also includes details of all the proposals reviewed by GTAC in 2000. GTAC assesses the ethical acceptability of proposals for gene therapy research on humans, taking into account the scientific merits and potential benefits and risks to patients. It also advises government on developments in this field.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.